Physician profile
Richard G Petty
NPI 1730334079
$2,850,709.96
in general payments reported to CMS, 2019-2025
11 companies · $765K in 2025
The $765K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336K · 2020: $189K · 2021: $194K · 2022: $332K · 2023: $393K · 2024: $642K · 2025: $765K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.2M · Consulting Fee: $252K · Travel and Lodging: $242K · Honoraria: $120K · Food and Beverage: $35K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,150,372.50 |
| Consulting Fee | $252,099.50 |
| Travel and Lodging | $242,477.93 |
| Honoraria | $120,031.50 |
| Food and Beverage | $34,871.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686,773.21 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $520,459.35 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $500,495.98 | 2023-2025 | Fanapt |
| Axsome Therapeutics, INC. | $470,504.32 | 2022-2025 | Auvelity |
| Allergan, INC. | $282,642.18 | 2019-2021 | |
| Alkermes, INC. | $177,975.29 | 2019-2023 | Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $156,610.86 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $28,431.53 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23,787.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $3,006.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.